tetano
Editor, Senior Moderator
J Med Virol
. 2023 Mar 25.
doi: 10.1002/jmv.28703. Online ahead of print.
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies Induced by the Third Dose of an Inactivated Vaccine: A Prospective Longitudinal Cohort Study at 21 Serial Time Points over 641 Days
Xin-Qi Zheng[SUP] 1 [/SUP], Qiu-Yan Xu[SUP] 1 [/SUP], Lin Xie[SUP] 1 [/SUP], Yun He[SUP] 1 [/SUP], Yong-Jing Wang[SUP] 1 [/SUP], Li-Li Liu[SUP] 1 2 [/SUP], Li-Rong Lin[SUP] 1 2 [/SUP], Tian-Ci Yang[SUP] 1 2 [/SUP]
Affiliations
Abstract
Given the prevalence of low-pathogenic but highly infectious Omicron variants, a cohort study was conducted to assess the response and duration of novel coronavirus-inactivated vaccine-induced antibodies one year after the third dose (day 641). Blood samples were collected and anti-spike neutralizing antibodies (neutralizing antibody), total antibodies against the receptor-binding domain of the spike protein (total antibody), and immunoglobulin G antibodies against the spike protein (IgG antibody) were determined. Antibody kinetics and attenuation were evaluated. The results showed that the levels of neutralizing, total, and IgG antibodies on day 641 were 98.05 IU/mL, 152.8 AU/mL, and 7.68 S/CO, respectively. Levels of anti-SARS-CoV-2 antibodies were higher in the younger subgroup than in the older subgroup at several time points after the second and third doses. The seropositive rate of neutralizing antibodies providing protection from infection or severe infection was 46.87% and 87.5%, and the seropositive rates of total antibody and IgG antibody were maintained at 100% and 90.63%, respectively. The half-lives of neutralizing, total, and IgG antibodies were 186.89, 363.04, and 417.50 days, respectively. Collectively, anti-SARS-CoV-2 antibodies may provide a certain degree of protection from infection one year after the third dose and high protection from severe infection. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; anti-SARS-CoV-2 antibody; neutralizing antibody; novel coronavirus-inactivated vaccine.
. 2023 Mar 25.
doi: 10.1002/jmv.28703. Online ahead of print.
Response and Duration of Serum Anti-SARS-CoV-2 Antibodies Induced by the Third Dose of an Inactivated Vaccine: A Prospective Longitudinal Cohort Study at 21 Serial Time Points over 641 Days
Xin-Qi Zheng[SUP] 1 [/SUP], Qiu-Yan Xu[SUP] 1 [/SUP], Lin Xie[SUP] 1 [/SUP], Yun He[SUP] 1 [/SUP], Yong-Jing Wang[SUP] 1 [/SUP], Li-Li Liu[SUP] 1 2 [/SUP], Li-Rong Lin[SUP] 1 2 [/SUP], Tian-Ci Yang[SUP] 1 2 [/SUP]
Affiliations
- PMID: 36965144
- DOI: 10.1002/jmv.28703
Abstract
Given the prevalence of low-pathogenic but highly infectious Omicron variants, a cohort study was conducted to assess the response and duration of novel coronavirus-inactivated vaccine-induced antibodies one year after the third dose (day 641). Blood samples were collected and anti-spike neutralizing antibodies (neutralizing antibody), total antibodies against the receptor-binding domain of the spike protein (total antibody), and immunoglobulin G antibodies against the spike protein (IgG antibody) were determined. Antibody kinetics and attenuation were evaluated. The results showed that the levels of neutralizing, total, and IgG antibodies on day 641 were 98.05 IU/mL, 152.8 AU/mL, and 7.68 S/CO, respectively. Levels of anti-SARS-CoV-2 antibodies were higher in the younger subgroup than in the older subgroup at several time points after the second and third doses. The seropositive rate of neutralizing antibodies providing protection from infection or severe infection was 46.87% and 87.5%, and the seropositive rates of total antibody and IgG antibody were maintained at 100% and 90.63%, respectively. The half-lives of neutralizing, total, and IgG antibodies were 186.89, 363.04, and 417.50 days, respectively. Collectively, anti-SARS-CoV-2 antibodies may provide a certain degree of protection from infection one year after the third dose and high protection from severe infection. This article is protected by copyright. All rights reserved.
Keywords: COVID-19; SARS-CoV-2; anti-SARS-CoV-2 antibody; neutralizing antibody; novel coronavirus-inactivated vaccine.